

A CONFERENCE OF NEW IDEAS IN CANCER - CHALLENGING DOGMAS

26 - 28 FEBRUARY 2016

TATA THEATRE, NCPA, Mumbai

Friday, February 26, 2016

Timings	Topics / Sessions	Faculty / Speaker
07.30 am	Registration	
08.30 - 08.40 am	Welcome	
Symposium 1: Has the molecular revolution reached the bedside? Chairpersons: Indraneel Mittra & Daniel Hayes		
08.40 - 09.00 am	Biological insights from the cancer genome	Akhilesh Pandey
09.00 - 09.20 am	How relevant are oncogenes in human cancer?	Aruna Ramachandran / Mathew Meyerson
09.20 - 09.40 am	How much of genomic data has translated into clinical practice?	Fabien Calvo
09.40 - 10.00 am	Discussion	
Key note address Chairpersons: Mammen Chandy & Arnie Purushotham		
10.00 - 10.30 am	Cancer research in need of a scientific revolution	Carlos Sonnenschein
10.30 - 11.00 am	Break	
Debate Moderators: Sudeep Gupta & Hemant Malhotra		
11.00 - 11.40 am	Debate 1: Has targeted therapy fulfilled its promise? Yes / For (20 min) No / Against (20 min)	Amit Oza Tito Fojo
11.40 - 12.00 noon	Discussion	
Invited Lectures: Future of cancer research - US and European perspectives Chairpersons: P. B. Desai & G. K. Rath		
12.00 - 12.30 pm	Invited lecture 1: Thinking Outside the Box in Cancer Research - Perspectives from the US NCI	Edward Trimble
12.30 - 01.00 pm	Invited lecture 2: Future of Oncology - European perspective	Alberto Costa
01.00 - 02.30 pm	Lunch and Poster Viewing	
Key note address Chairpersons: Ronald DePinho & S. V. S. Deo		
02.30 - 03.00 pm	Act of observation and its impact on cancer outcomes	Rajendra Badwe / Priyanka Pandey / Amit Dutt
Symposium 2: New ideas in cancer research - I Chairpersons: Vinod Raina & Ramesh Nimmagadda		
03.00 - 03.20 pm	Peri operative NSAIDs in breast cancer	Michael Retsky
03.20 - 03.40 pm	Novel PI3 kinase inhibitors: Bench to bedside	Varsha Gandhi
03.40 - 04.00 pm	Biological principles of metronomic therapy	Nicolas Andre
04.00 - 04.20 pm	Precision medicine: Lessons from the SHIVA trial	Christophe Le Tourneau
04.20 - 04.40 pm	Discussion	
04.40 - 05.00 pm	Break	
Key note address Chairpersons: Harit Chaturvedi & C. S. Pramesh		
05.00 - 05.30 pm	How relevant are the randomized controlled trials in clinical practice?	Ian Tannock
Symposium 3: Large data sets and their relevance to the patient Chairpersons: Susan Shurin & Fabien Calvo		
05.30 - 05.50 pm	RCT's and health outcome research	Chris Booth
05.50 - 06.10 pm	Omics and big data sets: Does statistical significance equal clinical relevance?	Rajiv Sarin
06.10 - 06.30 pm	Discussion	
06.45 - 08.00 pm	Opening Ceremony Chief Guest: Dr. R. Chidambaram, Principal Scientific Advisor to the Govt. of India	
08.00 - 10.00 pm	Inaugural Dinner	

Saturday, February 27, 2016

Timings	Topics / Sessions	Faculty / Speaker
08.00 am	Registration	
Symposium 4: Public health issues in cancer Chairpersons: Preetha Rajaraman & Rajesh Dikshit		
8.30 - 8.50 am	Problems and pitfalls in public health research	Matti Hakama
8.50 - 9.10 am	GWAS: Are risk variants biologically and clinically relevant?	Julian Peto
9.10 - 9.30 am	Time trends in cervical cancer: does it justify national vaccination / screening programmes in cervical cancer?	Freddie Bray
9.30 - 9.50 am	Environmental determinants of neoplasia: Does cancer start in the womb?	Ana Soto
9.50 - 10.10 am	Discussion	
Key note address Chairpersons: Matti Hakama & R. A. Badwe		
10.10 - 10.40 am	Harms of cancer screening	Michael Baum
10.40 - 11.10 am	Break	
Hospital Day Oration Function		
11.10 - 11.20 am	Welcome Address	RA Badwe
11.20 - 12.20 pm	Oration: The cure that does not come - Stalling innovation in the 21st century	Jan Vijg
12.20 - 12.30 pm	Valedictory function	
12.30 - 02.00 pm	Lunch and Poster Viewing	
Key note address Chairpersons: Jan Vijg & J. V. Divatia		
02.00 - 02.30 pm	The role of dead cell chromatin in cancer initiation, progression and metastasis	Indraneel Mittra
Symposium 5: Dead cell chromatin and cancer Chairpersons: Ian Tannock & Anita Borges		
02.30 - 02.50 pm	Cancer: But which cell is it anyway?	Sen Pathak
02.50 - 03.10 pm	Cancer metastasis: Which cell is it anyway?	Akshita Singh
03.10 - 03.30 pm	Is the metastatic tumour genetically similar to the primary?	Nikolas Stoecklein
03.30 - 03.50 pm	Clinical implications of apoptotic circulating tumour cells	Daniel Hayes
03.50 - 04.10 pm	Dead cell chromatin, tumour heterogeneity and therapy resistance	I. Mittra / Amit Dutt
04.10 - 04.30 pm	Discussion	
04.30 - 05.00 pm	Break	
Key note address Chairpersons: A. K. D'Cruz & Paul Sebastian		
05.00 - 05.30 pm	Cancer Moon Shot - Making Cancer History	Ronald DePinho
Debate Moderators: Michael Brada & Vineet Gupta		
05.30 - 06.10 pm	Debate 2: Is precision medicine an achievable goal? Yes / For (20 Min) No / Against (20 Min)	Hope Rugo Vinay Prasad / Tito Fojo
06.10 - 06.30 pm	Discussion	
07.30 pm onwards	Cultural programme and Conference Banquet at NCPA (Padma Vibhushan Pandit Shiv Kumar Sharma)	

Sunday, February 28, 2016

Timings	Topics / Sessions	Faculty / Speaker
Top scoring oral abstracts session (Detailed information in the following pages) Chairpersons: Clinical Research - Tapan Saikia & Pankaj Chaturvedi Basic Research - T. Rajkumar & Chitra Sarkar		
08.00 - 10.00 am	Abstracts: 36 (2 parallel sessions)	Platform presenters
10.00 - 10.30 am	Break	
Invited Lecture 3 Chairperson: Michael Retsky & Devang Khakhar		
10.30 - 11.00 am	Fractal geometry in oncogenesis	Michael Baum
Key note address Chairperson: Nagraj Huilgol & Somasundaram Subramanian		
11.00 - 11.30 am	Harnessing technology for cancer treatment - Who benefits?	Michael Brada
Symposium 6: The lure and promise of technology Chairperson: Alberto Costa & Shaleen Kumar		
11.30 - 11.50 am	Advanced technologies and global cancer outcomes	Mary Gospodarowicz
11.50 - 12.10 pm	The politics and economics of novel technologies	Richard Sullivan
12.10 - 12.30 pm	Technologies around the corner; promise and risks	David Jaffray
12.30 - 12.50 pm	Discussion	
12.50 - 02.00 pm	Lunch	
Symposium 7: The promise of cancer immunotherapy Chairpersons: Subrata Sinha & S. V. Chiplunkar		
02.00 - 02.20 pm	Biological principles of immunotherapy	Vijay Kuchroo
02.20 - 02.40 pm	Applications of immunotherapy	Gordon Freeman
02.40 - 03.00 pm	Discussion	
Symposium 8: New ideas in cancer research - II Chairpersons: Soumya Swaminathan & Rakesh Kumar		
03.00 - 03.20 pm	Attenuated bacterium <i>Listeria monocytogenes</i> as a new delivery platform for anticancer agents	Claudia Gravekamp
03.20 - 03.40 pm	Copper-depletion using tetrathiomolybdate: A phase II clinical study in high risk for recurrent breast cancer	Linda Vahdat
03.40 - 04.00 pm	Metronomic maintenance therapy improves outcome in triple negative breast cancer	Sripad Banavali
Invited lecture 4 Chairpersons: N. K. Ganguly & Arun Nanivadekar		
04.00 - 04.30 pm	Should the industry reconsider its approach to cancer drug discovery?	B. Khamar
04.30 - 05.00 pm	Break	
05.00 - 06.30 pm	Grand discussion and summing up Moderators: Ian Tannock & David Collingridge	Alberto Costa, RA Badwe, Ted Trimble, Neel Mittra, Daniel Hayes, Hope Rugo, Mike Brada, Tito Fojo, Soumya Swaminathan, Arnie Purushotham, N. K. Ganguly, Carlos Sonnenschein...
06.30 - 06.40 pm	Closing and Valedictory Function	

Sunday, February 28, 2016 (0800-1000 hours)

Top Scoring Oral Abstracts Session: Clinical Research

Chairpersons: Tapan Saikia & Pankaj Chaturvedi

Time (24-hrs. format)	Abstract ID	Abstract Details
0800-0810	OT61-001	<p>KPT-330, an inhibitor of CRM-1 in combination with proteasome inhibition enhances tumor suppression through transcriptional down regulation of surviving by inhibition of NFkB through increased nuclear localization of ikB</p> <p><u>J. S. Nair</u>¹, G. K. Schwartz¹</p> <p>Columbia University, New York, USA</p>
0810-0820	OT105-002	<p>Role of neo-adjuvant chemotherapy for organ preservation in oral cancer: A randomized controlled trial</p> <p><u>D. Chaukar</u>¹, K. Prabhash¹, S. Arya¹, S. Sharma¹, P. Rane¹, P. Pai¹, P. Chaturvedi¹, S. Nair¹, S. Kane¹, G. Pantvaidya¹, D. Nair¹, A. Deshmukh¹, A. K. D'Cruz¹</p> <p>¹Tata Memorial Hospital, Mumbai, India</p>
0820-0830	OT266-003	<p>Assessment of theranostic potential of Lu-177-Trastuzumab in HER2 expressing breast cancer patients</p> <p><u>J. Shukla</u>¹, P. Bhusari¹, R. Vatsa¹, G. Singh², A. Bal³, M. Parmar¹, D. K. Dhawan⁴, B. R. Mittal¹</p> <p>¹Department of Nuclear Medicine & PET, PGIMER Chandigarh, India ²Department of Surgery & PET, PGIMER Chandigarh, India ³Department of Histopathology, PGIMER Chandigarh, India ⁴Centre for Nuclear Medicine, Panjab University Chandigarh, India</p>
0830-0840	OT72-004	<p>Integrating epigenetics into personalized medicine</p> <p><u>M. J. Worsham</u>¹, K. M. Chen¹, J. K. Stephen¹, I. Datta¹, G. Divine¹</p> <p>¹Henry Ford Health System, Detroit, MI, USA</p>
0840-0850	OT56-005	<p>Head and Neck Cancer and Oncologic Emergencies</p> <p><u>C. Reyes-Gibby</u>¹</p> <p>¹University of Texas MD Anderson Cancer Center, Houston, TX, USA</p>
0850-0900	OT104-006	<p>Somatic Mutational Profile of 412 Cancer Targeted Genes of Pancreatic Ductal and Periampullary Adenocarcinoma in Indian Patient Population</p> <p>G. Saha¹, R. Singh¹, U. Chakravarti¹, D. Anchlia², S. Ghatak³, S. Gulati³, S. Ghosh², B. Roy¹, <u>N. Sikdar</u>¹</p> <p>¹Human Genetics Unit, Indian Statistical Institute, Kolkata, India ²Department of Surgery, Calcutta Medical Research Institute, Kolkata, India ³Department of General Surgery, Calcutta Medical College and Hospital, Kolkata, India</p>

Sunday, February 28, 2016 (0800-1000 hours)

Top Scoring Oral Abstracts Session: Clinical Research

Chairpersons: Tapan Saikia & Pankaj Chaturvedi

Time (24-hrs. format)	Abstract ID	Abstract Details
0900-0905	OF16-001	<p>Molecular characterization of MYOD1 and PIK3CA mutations in rhabdomyosarcomas</p> <p>M. Ramteke¹, <u>B. Rekhi</u>², P. Upadhyay¹, A. Dutt¹</p> <p>¹Integrated Genomics Laboratory, Advanced Centre for Treatment, Research and Education In Cancer, Tata Memorial Centre, Mumbai, India</p> <p>²Department of Surgical Pathology, Tata Memorial Centre, Parel, Mumbai, Maharashtra, India</p>
0905-0910	OF246-B015	<p>Chromatin from dead cells causes radiation-induced bystander effect</p> <p><u>S. Kirolikar</u>¹, M. Nobre¹, I. Mittra¹</p> <p>¹Translational Research Laboratory; Advanced Centre for Treatment, Research & Education in Cancer, Tata Memorial Centre, Navi Mumbai, India</p>
0910-0915	OF5-003	<p>Challenging the role of Frozen Section for margin assessment in oral squamous cell carcinoma</p> <p><u>A. Mishra</u>¹, P. Chaturvedi¹, S. Datta², S. V. Kane³, D. Nair¹, A. Garg¹</p> <p>¹Head & Neck Services, Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India</p> <p>²Narayana Superspeciality Hospital, Kolkata, India</p> <p>³Department of Pathology, Tata Memorial Hospital, Mumbai, India</p>
0915-0920	OF295-K025	<p>Straticyte: A Proteomic Signature Image Analysis Based Test for Predicting Risk of Cancer Development in Oral Lesions with Dysplasia</p> <p><u>R. Ralhan</u>^{1,2,4,5}, R. Gu⁵; P. G. Walfish^{1,2,3,5}, K. Pritzker⁵</p> <p>¹Alex and Simona Shnaider Research Laboratory in Molecular Oncology;</p> <p>²Joseph and Mildred Sonshine Family Centre for Head and Neck Diseases, Department of Otolaryngology-Head and Neck Surgery</p> <p>³Department of Medicine, Endocrine Division, Mount Sinai Hospital and University of Toronto</p> <p>⁴Department of Otolaryngology-Head and Neck Surgery, University of Toronto, Toronto, Ontario, Canada,</p> <p>⁵Proteocyte Diagnostics Inc., Toronto, Ontario, Canada</p>
0920-0925	OF70-005	<p>Can we predict molecular subtypes of medulloblastoma based on MRI? Encouraging data from a blinded study</p> <p><u>A. Dasgupta</u>¹, T. Gupta¹, S. Pungavkar², A. Janu³, N. Shirsat⁴, G. Chinnaswamy⁵, R. Jalali¹</p> <p>¹Department of Radiation Oncology, Tata Memorial Centre, Mumbai, India</p> <p>²Department of Radiodiagnosis, Global Hospital, Mumbai, India</p> <p>³Department of Radiodiagnosis, Tata Memorial Centre, Mumbai, India</p> <p>⁴Department of Neuro Oncology, Advanced Centre for Treatment, Research and Education in Cancer, India</p> <p>⁵Department of Paediatric Oncology, Tata Memorial Centre, Mumbai, India</p>

Sunday, February 28, 2016 (0800-1000 hours)

Top Scoring Oral Abstracts Session: Clinical Research

Chairpersons: Tapan Saikia & Pankaj Chaturvedi

Time (24-hrs. format)	Abstract ID	Abstract Details
0925-0930	OF141-006	<p>A prospective study to evaluate the pattern of lymphatic metastasis in relation to submandibular gland in the patients with carcinoma of the oral cavity</p> <p><u>A. Malik</u>¹, S. Nair¹, D. Nair¹, P. Chaturvedi¹</p> <p>¹Dept of Head & Neck Oncology, Tata Memorial Centre, Mumbai, India</p>
0930-0935	OF77-007	<p>Solid tumor cancer as a systems-biology disease: Mechanistic and clinical evaluation of the therapeutic effectiveness of murine renal adenocarcinoma cells in agarose macrobeads. (FDA BBIND 10091;NCT01053013, 02046174)</p> <p><u>B. H. Smith</u>¹, L. S. Gazda², N. Berman¹, P. C. Martis², M. A. Laramore², Z. P. Andrada¹, A. Nazarian¹, J. Thomas¹, E. Akahoho¹, A. Dudley², T. Parikh¹, A. J. Ocean³, T. J. Fahey III⁴, D. J. Wolf¹</p> <p>¹The Rogosin Institute, New York, NY, USA ²The Rogosin Institute-Xenia Division, Xenia, OH, USA ³Weill Cornell Medical College, New York, NY, USA ⁴New York-Presbyterian Hospitals, New York, NY, USA</p>
0935-0940	OF152-008	<p>Cytotoxic microenvironment in Angioimmunoblastic T cell lymphoma – When good comes from the bad</p> <p><u>T. Shet</u>¹, S. Epari¹, M. Sengar¹, H. Menon¹</p> <p>¹Department of Pathology and Adult hematolymphoid DMG, Tata Memorial Hospital, Parel, Mumbai, India</p>
0940-0945	OF262-009	<p>BRAF v600e mutation confers poor survival and lack of response to Conventional therapies in childhood low-grade glioma. A report from The PLGG taskforce, Toronto Canada.</p> <p><u>R. Krishnatry</u>¹, A. Arnaldo², M. Mistry², C. Ling², A. Lassaletta², E. Bouffet², C. Hawkins², U. Tabori²</p> <p>¹Consultant Radiation Oncologist, Mazumdar Shaw Cancer Center, Bangalore India ²The Hospital for Sick Children, Toronto, Canada</p>
0945-0950	OF281-010	<p>A novel approach to the management of metastatic solid tumors – Role of high dose radiation in inducing an immune response</p> <p><u>A. K. Anand</u>¹, V. Goel¹, A. Gulia¹</p> <p>¹Department of Radiation Oncology, Max Cancer Centre, Max Hospital, New Delhi</p>
0950-0955	OF175-011	<p>Epithelial-to-Mesenchymal Transition in Cerebral Metastases of Cancers: Genes, proteins and targets of therapy</p> <p>D. Jeevan¹, J. Cooper¹, A. Kwasnicki¹, A. Braun¹, R. Murali¹, <u>M. J. Uniyal</u>¹</p> <p>¹Department of Neurosurgery, New York Medical College, New York, USA</p>
0955-1000	OF193-012	<p>Raman spectroscopy for classification of high grade glioma from adjacent normal tissue: Towards surgical demarcation</p> <p>A. Hole¹, S. Mohanan¹, S. Chatterjee¹, E. Sridhar¹, A. Moiyadi¹, <u>C. M. Krishna</u>¹</p> <p>¹ACTREC, Tata Memorial Centre (TMC), Mumbai, India</p>

Sunday, February 28, 2016 (0800-1000 hours)

Top Scoring Oral Abstracts Session: Basic Sciences

Chairpersons: T. Rajkumar & Chitra Sarkar

Time (24-hrs. format)	Abstract ID	Abstract Details
0800-0810	OT176-001	<p>Preventing and treating hepatic metastatic colon and pancreatic cancers by targeting cell metabolism</p> <p><u>S. V. Jin</u>¹, A. Al-sadi¹</p> <p>¹Pharmacology Dept., Rutgers Univ.-Robert Wood Johnson Med. Sch., New Jersey, USA</p>
0810-0820	OT26-002	<p>Disrupting Protein: Protein Interactions to overcome Drug resistance</p> <p><u>S. V. Malhotra</u>¹</p> <p>¹Department of Radiation Oncology, Stanford University, Palo Alto, CA, USA</p>
0820-0830	OT30-003	<p>BCR-ABL mediated repression of mir-223 results in the activation of MEF2C and PTBP2 in chronic myeloid leukemia</p> <p><u>S. Chakraborty</u>¹</p> <p>¹Institute of Life Sciences, Nalco square, Bhubaneswar, Odisha, India</p>
0830-0840	OT244-004	<p>Circulating chromatin from cancer patients and / or those derived from dead cancer cells imparts cancer stem-cell like properties to NIH3T3 cells</p> <p><u>R. Chaubal</u>^{2,4}, N. Gardi², E. Kaur³, A. Gaikwad¹, P. Prasannan¹, S. Dutt³, A. Dutt², I. Mittra¹</p> <p>¹Translational Research Laboratory; Advanced Centre for Treatment, Research & Education in Cancer Navi Mumbai, India</p> <p>²Integrated Cancer Genomics Laboratory; Advanced Centre for Treatment, Research & Education in Cancer Navi Mumbai, India</p> <p>³DNA Repair and Chromatin Biology Laboratory; Advanced Centre for Treatment, Research & Education in Cancer Navi Mumbai, India</p> <p>⁴Department of Surgical Oncology, Tata Memorial Hospital Tata Memorial Centre ,Mumbai, India</p>
0840-0850	OT184-005	<p>Cabozantinib eradicates advanced murine prostate cancer by activating anti tumor innate immunity</p> <p><u>A. Patnaik</u>¹</p> <p>¹University of Chicago</p>
0850-0900	OT33-006	<p>The Role of Asap1 in Physiological Processes and Tumor Metastasis</p> <p><u>S. Saraswati</u>¹, C. Schreiber¹, W. Thiele², M. Rothley², N. Cremers¹, C. Korn³, H. Augustin³, J.P. Sleeman^{1,2}</p> <p>¹Centre for Biomedicine and Medical Technology Mannheim, Universitätsmedizin Mannheim, University of Heidelberg, Germany</p> <p>²Institute for Toxicology and Genetics, KIT Campus North, Karlsruhe, Germany</p> <p>³German Cancer Research Center (DKFZ) Heidelberg, Germany</p>

Sunday, February 28, 2016 (0800-1000 hours)

Top Scoring Oral Abstracts Session: Basic Sciences

Chairpersons: T. Rajkumar & Chitra Sarkar

Time (24-hrs. format)	Abstract ID	Abstract Details
0900-0905	OF43-001	<p>Drug resistance and Metastasis: New Perspectives of an Old Problem</p> <p><u>K. Mehta</u>¹</p> <p>¹Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston TX, USA</p>
0905-0910	OF117-002	<p>The clockwork of cancer metabolism reveals novel anticancer strategies</p> <p><u>B. Grimaldi</u>¹</p> <p>¹Istituto Italiano di Tecnologia, Genoa, Italy</p>
0910-0915	OF50-003	<p>Pro-oncogenic Role of NOTCH1 in Early Tongue Squamous Cell Carcinoma</p> <p><u>P. Upadhyay</u>¹, S. Nair², E. Kaur³, J. Aich¹, P. Dani¹, V. Sethunath¹, N. Gardi¹, P. Chandrani¹, M. Godbole¹, K. Sonawane², S. Kannan⁴, B. Agarwal⁵, S. Kane⁶, S. Dutt³, A. Dutt¹</p> <p>¹Integrated Genomics Laboratory, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, NaviMumbai, India</p> <p>²Division of Head and Neck Oncology, Department of Surgical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Navi Mumbai, India</p> <p>³Shilpee Laboratory, Advanced Centre for Treatment, Research and Education In Cancer, Tata Memorial Centre, Navi Mumbai, India</p> <p>⁴Advanced Centre for Treatment, Research and Education In Cancer, Tata Memorial Centre, Navi Mumbai, India</p> <p>⁵Department of Pathology, Advanced Centre for Treatment, Research and Education In Cancer, Tata Memorial Hospital, Tata Memorial Centre, Navi Mumbai, India</p> <p>⁶Department of Pathology, Tata Memorial Hospital, Tata Memorial Centre, Mumbai, India</p>
0915-0920	OF161-004	<p>Understanding therapy resistance in GBM using in vitro transcriptome analysis and orthotopic mouse models</p> <p><u>J. Nair</u>¹, E. Kaur¹, R. Thorat², N. Gardi³, K. Patkar¹, R. Chaubal³, P. Chaudhari⁴, A. Dutt³, S. Dutt¹</p> <p>¹Shilpee Dutt Laboratory, ACTREC, Tata Memorial Centre, Mumbai, India</p> <p>²Laboratory Animal Facility, ACTREC, Tata Memorial Centre, Mumbai, India</p> <p>³Amit Dutt Laboratory, ACTREC, Tata Memorial Centre, Mumbai, India</p> <p>⁴Small Animal Imaging Facility, ACTREC, Tata Memorial Centre, Mumbai, India</p>
0920-0925	OF68-005	<p>Evolution by Tumor Neofunctionalization: The Role of Heritable Tumors in Progressive Evolution.</p> <p>A. P. Kozlov¹, <u>Andrei Makashov</u></p> <p>¹Biomedical Center and Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russia</p>
0925-0930	OF51-007	<p>Single-cell metrics of the efficacy of CAR+ T cells</p> <p>G. Romain¹, H. Singh², I. Liadi¹, J. R. Adolacion¹, B. Roysam³, L. Cooper², <u>N. Varadarajan</u>¹</p> <p>¹Department of Chemical and Biomolecular Engineering, University of Houston, USA</p> <p>²MD Anderson Cancer Center, University of Texas, Houston, USA</p> <p>³Department of Electrical Engineering, University of Houston, USA</p>

Sunday, February 28, 2016 (0800-1000 hours)

Top Scoring Oral Abstracts Session: Basic Sciences

Chairpersons: T. Rajkumar & Chitra Sarkar

Time (24-hrs. format)	Abstract ID	Abstract Details
0930-0935	OF168-008	<p>Secretory phospholipase A2-IIA: emerging roles in stem cells regulation and cellular differentiation</p> <p><u>S. K. Waghmare</u>¹</p> <p>¹Stem Cell Biology Group, Waghmare Lab, ACTREC, Tata Memorial Centre, Mumbai, India</p>
0935-0940	OF182-009	<p>Therapeutic targeting of tumour cell specific metabolic reprogramming through the dynamic stabilization of native and misfolded state of nuclear receptor co-repressor (N-CoR)</p> <p><u>M. Khan</u>¹</p> <p>¹Department of Pathology, School of Medicine, AIMST University, Kedah, Malaysia</p>
0940-0945	OF1-010	<p>Impact of human papilloma virus status on the response of head and neck carcinomas cell lines to novel therapeutic agents</p> <p><u>A. Mahajan</u>^{1,2}, B. Ayaz³, N. Raulf¹, J. Bullenkamp⁴, Y.Suh¹, S.Thavaraj³, M. Tavassoli¹</p> <p>¹Department of Molecular Oncology, King's College London, London, UK ²Department of Radiodiagnosis, Tata Memorial Hospital, Parel, Mumbai, India ³Department of Oral Pathology, King's College London, London, UK ⁴Centre for Cell Death, Cancer and Inflammation (CCCI), UCL Cancer Institute, London, UK</p>
0945-0950	OF11-011	<p>A novel mechanism of homotypic cell fusion promote formation of Glioma resistance cells facilitated by NHEJ driven repair</p> <p><u>E. Kaur</u>¹, J. Nair¹, A. Kushwaha¹, A. Shetty¹, A. Srivastava¹, A. Moiyadi¹, S. Dutt¹</p> <p>¹Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai, India</p>
0950-0955	OF128-012	<p>Could be sigma-1 receptor a leading actor in the cancer pathway? A multidisciplinary approach to define its role in blocking metabolic stress response in cancer cells.</p> <p><u>E. Laurini</u>¹, G. Civenni², C. Monte², F. Sereni², G. Carbone², B. Wunsch³, M. Fermeiglia¹, C. Catapano², S. Prici¹</p> <p>¹MOSE-DEA, University of Trieste, Italy ²Institute of Oncology Research (IOR), Bellinzona, Switzerland ³Department of Pharmaceutical and Medicinal Chemistry, University of Münster, Germany</p>
0955-1000	OF283-013	<p>Expanding the 'druggable genome' using Structural Constraints and Dynamics- Innovative Use of Big and Smart Data</p> <p><u>P. Venkatraman</u>¹</p> <p>¹Protein Interacome Lab for Structural and Functional Biology ACTREC, TMC</p>